US Patent 11603348 Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods

Patent 11603348 was granted and assigned to Amorsa Therapeutics, Inc. on March, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

‌

Amorsa Therapeutics, Inc.

Current Assignee

‌

Amorsa Therapeutics, Inc.

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

116033480

Date of Patent

March 14, 2023

Patent Application Number

171969860

Date Filed

March 9, 2021

Patent Citations

‌

US Patent 10252982 Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods

Patent Primary Examiner

CPC Code

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11603348 Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API